Sage Group is attending BioEurope virtually Nov 2-4 and will be pleased to meet you! Please click here to setup a call with us or book on the Partnering sessions!

Sage is representing EpiAxis Therapeutics. We are seeking strategic partners to license their novel technology for epigenetic control of metastatic cancer. EpiAxis Therapeutics is a leading epigenetics company targeting the nuclear bound lysine-specific demethylase 1 (LSD1) enzyme. The company discovered the dual role that LSD1 plays in reprograming the epigenome in metastatic disease and has novel, best in class inhibitors, against this pivotal target. EpiAxis’ inhibitors r

The Sage Group is representing Quest Consumer Health Holdings, the owner of the OraMelts manufacturing facility and patent portfolio, in their search for one or more partners with which it can collaborate to expand the applications of its unique and highly successful OraMelts oral adhesive disc drug delivery technology. Proprietary products using this technology are already sold in major US pharmacy chains in Europe and Australia. The partnership may include an exclusive worl